An FDA official has said that the agency expects interchangeable biosimilars to come to market within 2 years and that the first interchangeable biosimilar will likely be reviewed by an FDA advisory committee of outside experts.
An FDA official has said that the agency expects interchangeable biosimilars to come to market within 2 years, possibly sooner, and that the first interchangeable biosimilar will likely be reviewed by an FDA advisory committee of outside experts.
Speaking at the Drug Information Association’s (DIA) annual conference in Chicago, FDA biosimilars lead Leah Christl, associate director for Therapeutic Biologics, OND Therapeutic Biologics and Biosimilars Team, also confirmed that the FDA has received 14 applications from 9 companies for biosimilars.
Christl said the FDA is reviewing industry stakeholders’ comments on the agency’s draft guidance on biosimilar interchangeability released in January 2017, and expects to issue either a revised guidance or a final guidance within 2 years. Industry stakeholders have noted several issues in their comments, including the naming and labeling for interchangeable products as well as the relationship between multiple interchangeable products for the same reference product.
Stakeholders want the FDA to address the issue of naming interchangeable biosimilar products in its final interchangeability guidance. The FDA’s final naming guidance issued in 2017 states that biosimilar and innovator biologic products will have the same core nonproprietary names followed by a distinguishable, but meaningless, lowercase 4-letter suffix—a ruling disliked by both biosimilar makers and innovators. Many stakeholders urged the FDA to use the same naming rules for interchangeable products as for biosimilar products.
The Pharmaceutical Research and Manufacturers of America (PhRMA), a trade organization that represents the pharmaceutical industry, noted that suffixes of interchangeable products should remain different from those of reference products to distinguish them from each other for patient safety and tracking purposes. “If multiple interchangeable versions of a single reference product were assigned the same suffix without an FDA determination that they were interchangeable to each other, there might be inadvertent substitution of these products,” PhRMA noted.
Stakeholders also pointed out that the FDA’s draft interchangeability guidance did not address labeling. They want biosimilar labeling to include interchangeability statements identifying whether or not interchangeability has been evaluated for the biosimilar, and include a definition for interchangeability.
There is also a demand for clarity on handling multiple interchangeable biosimilar products of the same reference product—stakeholders want the FDA to take steps to ensure that only an interchangeable biological product and its reference product are subject to automatic pharmacy substitution. Amgen, for example, asked the FDA to include a statement in the guidance that interchangeability does not reflect any relationship with another interchangeable product to the same reference product.
Finally, stakeholders asked the FDA to address confusion over physician-mediated switching, which is possible for interchangeable and non-interchangeable biosimilars, and pharmacy-level substitution, which is possible for interchangeable biosimilar products.
With patient protection their greatest concern, patient groups demanded the FDA take steps to protect patients from nonmedical switching involving non-interchangeable biosimilars. A number of comments from patient groups stated their concern that payers were, in effect, mandating pharmacy-level substitution for non-interchangeable biosimilars by removing innovator/reference products from formularies.
The Biologic Prescribers Collaborative has provided interchangeability recommendations to the FDA. Visit our infographic on the recommendations here.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.